Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
0.9300
-0.4400 (-32.12%)
At close: Aug 14, 2026, 4:00 PM EDT
0.8995
-0.0305 (-3.28%)
After-hours: Aug 14, 2026, 7:59 PM EDT
Daré Bioscience Revenue
Daré Bioscience had revenue of $187.55K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $1.37M. In the year 2025, Daré Bioscience had annual revenue of $1.03M with 10,429.36% growth.
Revenue (ttm)
$1.37M
Revenue Growth
+10,429.36%
P/S Ratio
10.20
Revenue / Employee
$56,914
Employees
24
Market Cap
13.93M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.03M | 1.02M | 10,429.36% |
| Dec 31, 2024 | 9.78K | -2.80M | -99.65% |
| Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
| Dec 31, 2022 | 10.00M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 80.00K | 74.00K | 1,233.33% |
| Dec 31, 2013 | 6.00K | -619.00K | -99.04% |
| Dec 31, 2012 | 625.00K | 619.00K | 10,316.67% |
| Dec 31, 2011 | 6.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 26.55M |
| Werewolf Therapeutics | 21.00M |
| Marker Therapeutics | 3.55M |
| Allarity Therapeutics | 345.00K |
| Cocrystal Pharma | 225.00K |
| Neuphoria Therapeutics | -13.27K |
DARE News
- 22 hours ago - Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 1 day ago - Daré Bioscience Earnings Call Transcript: Q2 2026 - Transcripts
- 1 day ago - Daré Bioscience Quarterly report: Q2 2026 - Filings
- 1 day ago - Daré Bioscience Earnings release: Q2 2026 - Filings
- 1 day ago - Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances - GlobeNewsWire
- 9 days ago - Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026 - GlobeNewsWire
- 18 days ago - Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx - GlobeNewsWire
- 26 days ago - Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities - GlobeNewsWire